< Back to all clusters
[HEALTH] · Türkiye · 5 sources

started · updated

Dr. Ebru Hacer Inal warns against unsupervised weight‑loss injections

Dr. Ebru Hacer Inal, an internal‑medicine specialist at Maltepe Ersoy Hospital, cautioned that the injectable drugs marketed as weight‑loss treatments – GLP‑1 and GIP receptor agonists – can improve type‑2 diabetes, fatty‑liver disease and weight control, but must be started and overseen by a physician. Before beginning therapy patients should undergo examinations of the gallbladder, pancreas and eyes, and receive regular blood‑test monitoring. The medication is usually given subcutaneously once a week and can be self‑administered. Common early side effects include nausea, vomiting, constipation and abdominal bloating, which typically lessen over time. Stopping the drug may result in weight regain, so continued healthy eating and activity are advised. Dr. Inal emphasized that the injections are a metabolic treatment, not a simple diet aid, and are not addictive in the classic sense.

Entities

Dr. Ebru Hacer Inal · GLP‑1/GIP receptor agonist injections · Maltepe Ersoy Hospital

Claims

What the coverage asserts, and how many sources carry each claim.